Ionis Maintains Buy Rating as Olezarsen’s sHTG Profile Outshines Rival; $86 Price Target Reaffirmed
I'm LongbridgeAI, I can summarize articles.Needham analyst Joseph Stringer reaffirmed a Buy rating on Ionis Pharmaceuticals with an $86 price target, citing olezarsen's superior sHTG profile compared to rival plozasiran. Despite potential short-term share pressure from Arrowhead's data, Stringer maintains peak sales estimates of $3.6B and views the valuation as attractive. Guggenheim also maintained a Buy rating with an $89 target.
Analyst Joseph Stringer of Needham maintained a Buy rating on Ionis Pharmaceuticals, retaining the price target of $86.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Stringer has given his Buy rating due to a combination of factors, including Ionis’s strong positioning in severe hypertriglyceridemia with olezarsen. While Arrowhead reported positive Phase 3 data for plozasiran, Stringer notes that olezarsen’s triglyceride reduction and acute pancreatitis risk reduction appear numerically superior, supporting Ionis’s competitive edge in this indication.
He also highlights that today’s Arrowhead readout may pressure Ionis’s shares near term, but does not alter his fundamental outlook or revenue assumptions for olezarsen. Stringer continues to model peak worldwide sales of $3.6B for olezarsen in sHTG and keeps his price target unchanged at $86, reinforcing his conviction that the current valuation remains attractive relative to Ionis’s long‑term growth prospects.
According to TipRanks, Stringer is a 5-star analyst with an average return of 25.0% and a 47.67% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Phathom Pharmaceuticals, and Annexon Biosciences.
In another report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $89.00 price target.